NCT05190991View on ClinicalTrials.gov

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

January 31, 2029

Conditions
Familial Mediterranean FeverFMF
Interventions
BIOLOGICAL

RPH-104

solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Trial Locations (8)

34093

RECRUITING

Istanbul University Istanbul Faculty of Medicine, Istanbul

34098

RECRUITING

Istanbul University Cerrahpasa Faculty of Medicine, Istanbul

119048

RECRUITING

FSBEI HE First Moscow State Medical University named after I.M. Sechenov, Moscow

125284

RECRUITING

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin, Moscow

191025

RECRUITING

Medical Technologies Ltd., Saint Petersburg

355000

RECRUITING

Terafarm, Llc, Stavropol

0001

RECRUITING

Center of Medical Genetics and Primary Health Care LLC, Yerevan

06230

RECRUITING

Hacettepe University Faculty of Medicine, Ankara

Sponsors

Collaborators (1)

Atlant Clinical LLC
All Listed Sponsors
collaborator

Atlant Clinical LLC

UNKNOWN

collaborator

Unimed Laboratories

INDUSTRY

collaborator

Data Management 365

INDUSTRY

collaborator

R-Pharm JSC

UNKNOWN

collaborator

TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd.

UNKNOWN

collaborator

Exacte Labs LLC

INDUSTRY

collaborator

Key Stat LLC

UNKNOWN

lead

R-Pharm International, LLC

INDUSTRY

NCT05190991 - Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever | Biotech Hunter | Biotech Hunter